{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:44:59Z","timestamp":1758127499964,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00415-022-11097-9","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T04:04:31Z","timestamp":1648613071000},"page":"4557-4559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-3177","authenticated-orcid":false,"given":"Cristian","family":"Deana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Bagatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Battezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Pecori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Lorenzut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Tuniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"11097_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/ene.12883","volume":"23","author":"\u00d8 Torkildsen","year":"2016","unstructured":"Torkildsen \u00d8, Myhr KM, B\u00f8 L (2016) Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 23:18\u201327. https:\/\/doi.org\/10.1111\/ene.12883","journal-title":"Eur J Neurol."},{"issue":"4","key":"11097_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S et al (2015) Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol 15(4):273\u2013279. https:\/\/doi.org\/10.1136\/practneurol-2015-001139","journal-title":"Pract Neurol"},{"issue":"Suppl 6","key":"11097_CR3","doi-asserted-by":"publisher","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","volume":"16","author":"A Doshi","year":"2016","unstructured":"Doshi A, Chataway J (2016) Multiple sclerosis, a treatable disease. Clin Med (Lond) 16(Suppl 6):s53\u2013s59. https:\/\/doi.org\/10.7861\/clinmedicine.16-6-s53","journal-title":"Clin Med (Lond)"},{"issue":"5","key":"11097_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S et al (2010) Clarity study group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 362(5):416\u201326","journal-title":"N Engl J Med."},{"issue":"3","key":"11097_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1468-1331.2008.02433.x","volume":"16","author":"T Kopadze","year":"2009","unstructured":"Kopadze T, D\u00f6bert M, Leussink VI et al (2009) Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 16(3):409\u2013412. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02433.x","journal-title":"Eur J Neurol"},{"issue":"12","key":"11097_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1177\/1352458517727603","volume":"24","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S et al (2018) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler 24(12):1594\u20131604. https:\/\/doi.org\/10.1177\/1352458517727603","journal-title":"Mult Scler"},{"issue":"6","key":"11097_CR7","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/1352458517694431","volume":"23","author":"M Sheikh-Taha","year":"2017","unstructured":"Sheikh-Taha M, Corman LC (2017) Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler 23(6):872\u2013874. https:\/\/doi.org\/10.1177\/1352458517694431","journal-title":"Mult Scler"},{"issue":"6","key":"11097_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamaneurol.2016.0146","volume":"73","author":"H Penkert","year":"2016","unstructured":"Penkert H, Delbridge C, Wantia N et al (2016) Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol 73(6):757\u2013759. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0146","journal-title":"JAMA Neurol"},{"issue":"2","key":"11097_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/jnnp-2020-324534","volume":"92","author":"MT Wijburg","year":"2021","unstructured":"Wijburg MT, Warnke C, McGuigan C et al (2021) Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. J Neurol Neurosurg Psychiatry 92(2):177\u2013188. https:\/\/doi.org\/10.1136\/jnnp-2020-324534","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11097_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/1352458519854162","volume":"26","author":"C Scarpazza","year":"2020","unstructured":"Scarpazza C, Signori A, Cosottini M et al (2020) Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. Mult Scler 26:1227\u20131236","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T16:32:00Z","timestamp":1658161920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["11097"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11097-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethics Committee approval was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained by patient\u2019s relatives before publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}